Breaking Down Kinnevik AB Financial Health: Key Insights for Investors

Dive into Kinnevik AB's financial snapshot where its core companies delivered an average revenue growth of over 35% in H1 2025, led by TravelPerk whose annualized revenues jumped to more than USD 275 million in Q2 2025 (from USD 200 million at year-start), while the private portfolio's fair value rose 3% in SEK (and 5% in constant currencies) in Q2 - all against a backdrop of a reported net loss of SEK 2.4 billion in H1 2025 and currency-related NAV headwinds of SEK 0.4 billion in Q3 2025; strategic activity included investments of SEK 860 million in Q2 (with SEK 333 million into Tandem Health), a net cash position around SEK 8.6-9.6 billion across Q2-Q3 2025, repaid bonds of SEK 1.5 billion in Q1, and a NAV that rose to SEK 37.5 billion by end-Q3 - context every investor needs before digging into revenue trends, profitability shifts, balance-sheet flexibility, valuation movements and risk exposure across high-performing holdings like Spring Health, TravelPerk, Pleo, Cityblock and Mews.

Kinnevik AB (0RH1.L) - Revenue Analysis

Kinnevik AB's first half of 2025 revenue picture shows strong top-line momentum across its core holdings and active portfolio deployment. Operational performance in the core companies, targeted investments in growth names and FX sensitivity to SEK are the main drivers behind the headline figures below.

• Core companies average revenue growth: >35% in H1 2025.
• TravelPerk annualized revenues: USD 275 million in Q2 2025 (up from USD 200 million at start of 2025).
• Private portfolio fair value change in Q2 2025: +3% in SEK, +5% in constant currencies.
• FX impact on NAV in Q3 2025: negative SEK 0.4 billion.
• Investments in Q2 2025: total SEK 860 million, including SEK 333 million to Tandem Health.
• High-performing core contributors (Spring Health, TravelPerk, Pleo, Cityblock, Mews) account for over 50% of portfolio returns.

Key revenue dynamics to monitor going forward include continued growth rates at TravelPerk and other scale-ups, currency swings affecting NAV translation, and incremental investments (e.g., Tandem Health) that reallocate capital toward high-growth segments. Further context on corporate history and strategy is available here: Kinnevik AB: History, Ownership, Mission, How It Works & Makes Money

Kinnevik AB (0RH1.L) - Profitability Metrics

Kinnevik AB's recent reporting cycle shows mixed signals: underlying operational improvements alongside continuing headline losses. The numbers below isolate profitability drivers, portfolio revaluations and capital deployment through H1-Q3 2025.

• Core companies improved EBITDA margins by 4 percentage points year‑on‑year in H1 2025, reflecting tighter cost control and improved unit economics.
• Despite strong revenue growth at several holdings, Kinnevik reported a net loss of SEK 2.4 billion in H1 2025, driven by valuation adjustments, one‑off items and continued investment spend.
• The private portfolio's fair value increased by 3% in SEK and 5% in constant currencies in Q2 2025, supported by solid operational progress across key holdings.
• Currency fluctuations negatively impacted Net Asset Value (NAV) by SEK 0.4 billion in Q3 2025, underlining FX sensitivity given Kinnevik's international exposures.
• Kinnevik invested SEK 860 million in Q2 2025, including SEK 333 million allocated to Tandem Health as part of ongoing portfolio rebalancing and growth funding.
• High‑performing core companies - Spring Health, TravelPerk, Pleo, Cityblock and Mews - now account for over 50% of the portfolio value, delivering the bulk of recent valuation upside.

Key operational and valuation drivers to monitor going forward include continued EBITDA margin expansion at core companies, FX volatility effects on NAV, and the pace of follow‑on investments into high‑conviction assets such as Tandem Health. For broader strategic context, see Mission Statement, Vision, & Core Values (2026) of Kinnevik AB.

Kinnevik AB (0RH1.L) - Debt vs. Equity Structure

Kinnevik entered 2025 with a conservative balance between cash-rich flexibility and selective investment activity. The company's net cash and debt movements through Q1-Q3 2025 underscore a deliberate deleveraging and active portfolio deployment strategy focused on high-growth, high-performing holdings.

• Net cash of SEK 9.6 billion at end-Q2 2025, reflecting strong liquidity.
• Repayment of SEK 1.5 billion in bonds upon maturity during Q1 2025, reducing gross debt.
• Net cash position of SEK 8.6 billion at end-Q3 2025, preserving flexibility for strategic investments.
• Invested SEK 860 million in Q2 2025, including SEK 333 million to Tandem Health, showing active portfolio allocation.
• Concentration on top-performing portfolio companies (Spring Health, TravelPerk, Pleo, Cityblock, Mews) that together represent over 50% of portfolio value.

Key implications for investors:

• Balance sheet strength: net cash near SEK 9-10 billion across mid-2025 quarters provides a buffer against market volatility and funds for opportunistic investments.
• Lower interest and refinancing risk after the SEK 1.5 billion bond repayment in Q1 2025.
• Active capital deployment: SEK 860 million invested in Q2 2025 (with SEK 333 million to Tandem Health) signals willingness to support growth in portfolio companies rather than hoarding cash.
• Concentration in high-performing names (Spring Health, TravelPerk, Pleo, Cityblock, Mews) that constitute >50% of portfolio value can drive returns but increases single-portfolio exposure risk.

For more background on the company's strategy, history and ownership context see: Kinnevik AB: History, Ownership, Mission, How It Works & Makes Money

Kinnevik AB (0RH1.L) - Liquidity and Solvency

• Net cash position: SEK 9.6 billion (end Q2 2025)
• Net cash position: SEK 8.6 billion (end Q3 2025)
• Bond repayment: SEK 1.5 billion repaid at maturity (Q1 2025)
• Investment activity: SEK 860 million invested in Q2 2025, including SEK 333 million into Tandem Health
• Concentration in high-performing core companies - Spring Health, TravelPerk, Pleo, Cityblock, Mews - which generate over 50% of portfolio returns

Kinnevik AB (0RH1.L) - Valuation Analysis

• NAV (end Q3 2025): SEK 37.5 billion (+2% QoQ)
• Private portfolio fair value (Q2 2025): +3% in SEK; +5% in constant currencies
• FX impact (Q3 2025): -SEK 0.4 billion
• Investments (Q2 2025): SEK 860 million total; SEK 333 million to Tandem Health
• Net cash position (end Q3 2025): SEK 8.6 billion
• Core high-performing companies (comprising >50% of portfolio): Spring Health, TravelPerk, Pleo, Cityblock, Mews

Kinnevik AB (0RH1.L) - Risk Factors

• Currency exposure: currency fluctuations negatively impacted NAV by SEK 0.4 billion in Q3 2025, underlining FX sensitivity across an international portfolio.
• Profitability pressure: the company reported a net loss of SEK 2.4 billion in H1 2025, reflecting challenging mark-to-market effects and operating losses at certain holdings.
• Capital deployment vs. preservation: Kinnevik invested SEK 860 million in Q2 2025 (including SEK 333 million to Tandem Health), balancing growth investments with the need to preserve liquidity.
• Concentration and performance risk: over half the portfolio value is driven by a handful of high-performing core companies (Spring Health, TravelPerk, Pleo, Cityblock, Mews), creating concentration risk if any underperform.
• Liquidity buffer and flexibility: Kinnevik's reported net cash position of SEK 8.6 billion at the end of Q3 2025 provides flexibility for strategic investments but also sets expectations for stewardship of that cash.

• Operational risk: execution setbacks at core companies could materially affect consolidated valuations and realized returns.
• Market risk: public market volatility and private-markets revaluations can widen reported losses in interim periods (illustrated by H1 2025 result).
• FX risk management: the SEK 0.4 billion NAV hit shows limited insulation from currency swings; hedging effectiveness and geographic revenue mixes matter.
• Reinvestment risk: preserving the SEK 8.6 billion net cash while deploying capital at attractive risk-adjusted returns remains a key governance challenge.
• Concentration risk: reliance on a few high-performing names increases sensitivity to company-specific news and sector cycles.

Kinnevik AB (0RH1.L) - Growth Opportunities

• Core companies delivered average revenue growth >35% in H1 2025, reflecting scalable unit economics and accelerating demand.
• TravelPerk scaled rapidly: annualized revenues surpassed USD 275 million in Q2 2025 (from ~USD 200 million at the start of 2025), evidencing a >37% increase year-to-date.
• Active portfolio deployment: total invested SEK 860 million in Q2 2025, including SEK 333 million directed to Tandem Health to support growth and product expansion.
• High-conviction holdings - Spring Health, TravelPerk, Pleo, Cityblock and Mews - account for over 50% of the portfolio by value, concentrating upside in market leaders.
• Liquidity buffer: net cash position of SEK 8.6 billion at end-Q3 2025 enables follow-on funding, selective M&A or opportunistic buybacks.

• Growth drivers: category leadership in employee mental health, corporate travel, SME finance and hospitality software; strong unit economics in scaling markets; follow-on capital to accelerate product-market fit.
• Execution levers: continued capital allocation to high-return assets, selective M&A, and leveraging SEK 8.6bn liquidity for optionality.
• Key sensitivities: macro travel demand recovery, competitive dynamics in fintech and health tech, and valuation re-rating across public markets.